Dublin, Nov. 09, 2022 (GLOBE NEWSWIRE) -- The "The US Anesthesia Drugs and Devices Market: Analysis By segment, By Type, By Drug product, By Device Product, Size And Trends With Impact of COVID-19 and Forecast up to 2027" report has been added to ResearchAndMarkets.com's offering.
The US anesthesia drugs and devices market in 2021 was valued at US$5.99 billion. The market value is predicted to reach US$8.88 billion by 2027. Anesthesia is the use of medicines to prevent pain during surgery and other procedures. They may be given by injection, inhalation, topical lotion, spray, eye drops, or skin patch. Anesthesia can cause one to have a loss of feeling or awareness.
The market is expected to grow at a CAGR of 6.80% during the forecast period of 2022-2027. Due to increasing number of surgeries, aging population with increasing chronic conditions, and advancements in anesthesia technologies, the market for anesthesia drugs and devices would grow in the years to come.
Market Segmentation Analysis:
By Segment: The report provides the bifurcation of the market into two categories based on the segment: anesthesia drugs and anesthesia devices. In 2021, anesthesia drugs segment held a major share of more than 55% in the market. On the other hand, the anesthesia devices segment is expected to grow at a significant CAGR in the forthcoming years owing to the rising healthcare expenditure in the region.
By Type: On the basis of type, the US anesthesia drugs market is divided into three types namely general, local and other anesthesia. In 2021, general anesthesia drug segment held a major share of more than 39% in the market. This was being followed by local anesthesia drugs. R&D activities in the pharmaceutical industry to formulate novel anesthesia drug is expected to provide remunerative opportunities for expansion of the US other anesthesia drugs market during forecast period.
By Device Product: The report provides the bifurcation of the market into three segments based on the device product: advanced, basic and integrated. In 2021, advanced segment held a major share of 62% in the market. This was being followed by integrated anesthesia device. The constant development in the field of the anesthesia monitoring devices and high demand for the better monitoring devices are also anticipated to push the growth in the US advanced anesthesia monitoring devices market.
By Drug Product: The report provides the bifurcation of the market into seven segments based on the drug product: Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Prilocaine, Benzocaine and Other Local Anesthetics. In 2021, Lidocaine anesthesia drug segment held a major share of 32% in the market. This was being followed by Bupivacaine, Ropivacaine. The market is anticipated to propel during forecasted years owing to the expanding patient population and the rise in medical and surgical procedures.
Market Dynamics:
Growth Drivers
- Rising Geriatric Population
- Growing Healthcare Expenditure
- Increase in Monitored Anesthesia Use
- Increase In Number Of Approvals For Anesthesia Drugs
Challenges
- Side Effects of Anesthesia
- Lack of Skilled Anesthesiologist
Market Trends
- Escalating Establishment of Ambulatory Surgical Centers (ASC)
- Technological Enhancement of Anesthesia Devices
Key Topics Covered:
1. Executive Summary
2. Introduction
3. Market Analysis
4. Impact of COVID-19
5. Market Dynamics
6. Competitive Landscape
7. Company Profiles
Companies Mentioned
- KKR & Co. Inc. (Envision Healthcare Corporation)
- Baxter International Inc.
- Blackstone (TeamHealth)
- Becton, Dickinson and Company
- Braun (B. Braun Avitum AG)
- 3M Company
- Abbvie Inc.
- Teleflex Incorporated
- Dragerwerk AG & Co. KGaA
- AstraZeneca Plc
- Abbott Laboratories
- General Electric Company
- ICU Medical, Inc
- SunMed LLC
For more information about this report visit https://www.researchandmarkets.com/r/zgf5hg
